TiGenix : TiGenix to host webcast for its 2015 half-year results on 15 September
(Thomson Reuters ONE) -
PRESS RELEASE
TiGenix to host webcast for its 2015 half-year results on 15 September
Leuven (BELGIUM) - 10 September, 2015 - TiGenix NV (Euronext Brussels: TIG), an
advanced biopharmaceutical company focused on developing and commercialising
novel therapeutics from its proprietary platforms of allogeneic expanded stem
cells, will announce its half-year results for 2015 on Tuesday 15 September
2015 at 17:45 CET.
TiGenix CEO, Eduardo Bravo, and CFO, Claudia D'Augusta, will host a conference
call and webcast during which the half-year results for 2015 will be presented,
followed by a Q&A session. This event will be held on Tuesday 15 September 2015
at 18.45 CET/12.45 pm EDT.
Please dial one of the following numbers to participate:
London, United Kingdom: +44(0)20 3427 1905
New York, USA: +1646 254 3361
Paris, France: +33(0)1 76 77 22 27
Brussels, Belgium: +32(0)2 620 0138
Madrid, Spain: +3491 114 6583
Montreal, Canada: +1514 841 2154
Amsterdam, Netherlands: +31(0)20 716 8256
Stockholm, Sweden: +46(0)8 5033 6538
Confirmation Code: 9894390
The webcast can be followed live online via the link: http://edge.media-
server.com/m/p/g4kvinkh
The press release and the webcast slide presentation will be made available in
the Newsroom section of the TiGenix website. A replay of the webcast will be
available on the website shortly after the live webcast has finished.
For more information
Claudia D'Augusta
Chief Financial Officer
T: +34 91 804 92 64
claudia.daugusta(at)tigenix.com
Ana Pombo
Strategic Planning and IR Manager
T: + 34 91 804 92 64
ana.pombo(at)tigenix.com
About TiGenix
TiGenix NV (Euronext Brussels: TIG) is an advanced biopharmaceutical company
focused on developing and commercialising novel therapeutics from its
proprietary platforms of allogeneic, or donor-derived, expanded stem cells. Two
products from the adipose-derived technology platform are currently in clinical
development. Cx601 is in Phase III for the treatment of complex perianal
fistulas in Crohn's disease patients. Cx611 has completed a Phase I/II trial in
rheumatoid arthritis, as well as a Phase I sepsis challenge trial. Effective as
of July 31, 2015, TiGenix acquired Coretherapix, whose lead cellular product
(AlloCSC-01) is currently in a Phase II clinical trial in acute myocardial
infarction (AMI). Coretherapix is planning to initiate the clinical evaluation
of AlloCSC-01 in the chronic setting as well and is also involved in the pre-
clinical development of a pharmaceutical formulation of growth factors to treat
AMI. Finally, TiGenix also developed ChondroCelect, an autologous cell therapy
product for cartilage repair of the knee, which was the first Advanced Therapy
Medicinal Product (ATMP) to be approved by the European Medicines Agency (EMA).
From June 2014, the marketing and distribution rights of ChondroCelect were
exclusively licensed to Sobi for the European Union (except for Finland, where
it is distributed by the Finnish Red Cross Blood Service), Norway, Russia,
Switzerland and Turkey, and the countries of the Middle East and North Africa.
TiGenix is headquartered in Leuven (Belgium) and has operations in Madrid
(Spain).
For more information, please visit www.tigenix.com
Forward-looking information
This document may contain forward-looking statements and estimates with respect
to the anticipated future performance of TiGenix and the market in which it
operates. Certain of these statements, forecasts and estimates can be recognised
by the use of words such as, without limitation, "believes", "anticipates",
"expects", "intends", "plans", "seeks", "estimates", "may", "will" and
"continue" and similar expressions. They include all matters that are not
historical facts. Such statements, forecasts and estimates are based on various
assumptions and assessments of known and unknown risks, uncertainties and other
factors, which were deemed reasonable when made but may or may not prove to be
correct. Actual events are difficult to predict and may depend upon factors that
are beyond the Company's control. Therefore, actual results, the financial
condition, performance or achievements of TiGenix, or industry results, may turn
out to be materially different from any future results, performance or
achievements expressed or implied by such statements, forecasts and estimates.
Given these uncertainties, no representations are made as to the accuracy or
fairness of such forward-looking statements, forecasts and estimates.
Furthermore, forward-looking statements, forecasts and estimates only speak as
of the date of the publication of this document. TiGenix disclaims any
obligation to update any such forward-looking statement, forecast or estimates
to reflect any change in the Company's expectations with regard thereto, or any
change in events, conditions or circumstances on which any such statement,
forecast or estimate is based, except to the extent required by Belgian law.
This announcement is distributed by GlobeNewswire on behalf of
GlobeNewswire clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: TiGenix via GlobeNewswire
[HUG#1951189]
Unternehmensinformation / Kurzprofil:
Bereitgestellt von Benutzer: hugin
" alt="DTS8 Seeks Proposals from Coffee Roasting Companies in USADatum: 10.09.2015 - 19:00 Uhr
Sprache: Deutsch
News-ID 419352
Anzahl Zeichen: 6683
contact information:
Town:
Leuven
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 155 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"TiGenix : TiGenix to host webcast for its 2015 half-year results on 15 September"
steht unter der journalistisch-redaktionellen Verantwortung von
TiGenix (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
